IRAK1 is a critical mediator of low molecular weight hyaluronic acid-induced stemness in high-grade serous ovarian cancer
Standing, D.; Dandawate, P.; Gunewardena, S.; Covarrubias-Zambrano, O.; Roby, K. F.; Khabele, D.; Jewell, A.; Tawfik, O.; Bossmann, S. H.; Godwin, A. K.; Weir, S. J.; Jensen, R. A.; Anant, S.
Show abstract
Advanced epithelial ovarian cancer (EOC) survival rates are dishearteningly low, with [~]25% surviving beyond 5 years. Evidence suggests that cancer stem cells (CSCs) contribute to acquired chemoresistance and tumor recurrence. Here, we show that IRAK1 is upregulated in EOC tissues, and enhanced expression correlates with poorer overall survival. IRAK1 and BRCA1/2 mutation status are mutually exclusive. Moreover, low molecular weight hyaluronic acid (LMW HA), which is abundant in malignant ascites from patients with advanced EOC, induced IRAK1 phosphorylation leading to STAT3 activation and enhanced spheroid formation. Knockdown of IRAK1 impaired tumor growth in peritoneal disease models, and impaired HA-induced spheroid growth and STAT3 phosphorylation. Finally, we determined that TCS2210, a known inducer of neuronal differentiation in mesenchymal stem cells, is a selective inhibitor of IRAK1. TCS2210 significantly inhibited EOC growth in vitro and in vivo both as monotherapy, and in combination with cisplatin. Collectively, these data demonstrate IRAK1 as a druggable target for EOC.
Matching journals
The top 11 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Cancer associated fibroblasts serve as an ovarian cancer stem cell niche through noncanonical Wnt5a signaling 96%
- A patient-derived ovarian cancer organoid platform to study susceptibility to natural killer cells 96%
- Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer 94%
Similar papers in this journal
- Pharmacologically targeting KRASG12D in PDAC models:tumor cell intrinsic and extrinsic impact 96%
- Biomarker-guided treatment strategies for ovarian cancer identified from a heterogeneous panel of patient-derived tumor xenografts 96%
- Systematic analysis uncovers SYK dependency in NF1LoF melanoma cells 95%
Similar papers in this journal
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 96%
- Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2 95%
- Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death 95%
Similar papers in this journal
Similar papers in this journal
- EZH2 inhibition promotes tumor immunogenicity in lung squamous cell carcinomas 96%
- p300 KAT regulates SOX10 stability and function in human melanoma 94%
- Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibition 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.